Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized phase II trial.

被引：0
|
作者：
Pectasides, D
Farmakis, D
Pectasides, M
Kostopoulou, V
Nikolaou, M
Koumpou, M
Gaglia, A
Kountourakis, P
Mylonakis, N
Economopoulos, T
机构：
[1] Attikon Univ Hosp, Athens, Greece
[2] Metaxas Mem Hosp, Piraeus, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7033
引用
收藏
页码：625S / 625S
页数：1
相关论文
共 50 条
  • [1] Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial
    Pectasides, D
    Pectasides, M
    Farmakis, D
    Kostopoulou, V
    Nikolaou, M
    Gaglia, A
    Koumpou, M
    Mylonakis, N
    Xiros, N
    Economopoulos, T
    Raptis, SA
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (02) : 294 - 299
  • [2] Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
    Georgoulias, V
    Papadakis, E
    Alexopoulos, A
    Stavrinidis, E
    Bania, E
    Rapti, A
    Grigoratou, T
    Kouroussis, C
    Kakolyris, S
    Samonis, G
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S249 - S249
  • [3] Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial
    Serke, M
    Schoenfeld, N
    Loddenkemper, R
    [J]. ANTICANCER RESEARCH, 2004, 24 (2C) : 1211 - 1216
  • [4] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [6] Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
    Cortinovis, Diego
    Bidoli, Paolo
    Cullura, Daniela
    Lorusso, Vito
    Ardizzoia, Antonio
    Amoroso, Vito
    Bandera, Mauro
    Aitini, Enrico
    Fusi, Alberto
    Zilembo, Nicoletta
    Radula, Daniela
    Bajetta, Emilio
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 405 - 411
  • [7] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)
    Sovak, M. A.
    Lutzker, S.
    Guensch, L.
    Joyce, M.
    Schwartz, S.
    Wu, Y.
    Zheng, L.
    Aisner, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: A phase I/II trial
    Kiura, Katsuyuki
    Takigawa, Nagio
    Segawa, Yoshihiko
    Tabata, Masahiro
    Shibayama, Takuo
    Gemba, Kenichi
    Bessho, Akihiro
    Fujimoto, Nobukazu
    Takata, Khiro
    Hotta, Katsuyuki
    Fujiwara, Keiichi
    Tokuda, Yoshiyuki
    Kuyama, Shoichi
    Shinkai, Tetsu
    Ueoka, Hiroshi
    Tanimoto, Mitsune
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (01) : 44 - 50
  • [9] Docetaxel plus ramucirumab (DR) versus docetaxel plus placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.
    Hosomi, Yukio
    Yoh, Kiyotaka
    Kasahara, Kazuo
    Yamada, Kazuhiko
    Takahashi, Toshiaki
    Tanaka, Kaoru
    Hida, Toyoaki
    Yoshioka, Hiroshige
    Kato, Terufumi
    Takeda, Koji
    Nishio, Makoto
    Sakai, Hiroshi
    Maemondo, Makoto
    Takenoyama, Mitsuhiro
    Nokihara, Hiroshi
    Tatsumi, Masumi
    Nakamura, Takashi
    Enatsu, Sotaro
    Tamura, Tomohide
    Nakagawa, Kazuhiko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.
    Fang, Yong
    Pan, Hongming
    Shou, Jiawei
    Hong, Wei
    Guo, Qunyi
    Yang, Xinmei
    Zhu, Dan
    Chen, Jun
    Lu, Liqin
    Rao, Chuangzhou
    Lan, Fen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345